 Connection
Joseph Saseen to Dyslipidemias
This is a "connection" page, showing publications Joseph Saseen has written about Dyslipidemias.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.745 |
|
|
|
-
Miller AE, Hansen LB, Saseen JJ. Switching statin therapy using a pharmacist-managed therapeutic conversion program versus usual care conversion among indigent patients. Pharmacotherapy. 2008 May; 28(5):553-61.
Score: 0.243
-
Marrs JC, Saseen JJ. Dyslipidemia control in indigent patients receiving medication assistance compared with insured patients. Pharmacotherapy. 2008 May; 28(5):562-9.
Score: 0.243
-
Blumenthal RS, Morris PB, Gaudino M, Johnson HM, Anderson TS, Bittner VA, Blankstein R, Brewer LC, Cho L, de Ferranti SD, Gianos E, Gluckman TJ, Gradney KF, Isiadinso I, Lloyd-Jones DM, Marrs JC, Martin SS, McLain KH, Mehta LS, Mora S, Mulugeta WM, Natarajan P, Navar AM, Orringer CE, Polonsky TS, Reynolds HR, Saseen JJ, Shapiro MD, Soffer DE, Tynes SA, Villavaso CD, Virani SS, Wilkins JT. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026 Apr 28; 153(17):e1154-e1276.
Score: 0.209
-
Blumenthal RS, Morris PB, Gaudino M, Johnson HM, Anderson TS, Bittner VA, Blankstein R, Brewer LC, Cho L, de Ferranti SD, Gianos E, Gluckman TJ, Gradney KF, Isiadinso I, Lloyd-Jones DM, Marrs JC, Martin SS, McLain KH, Mehta LS, Mora S, Mulugeta WM, Natarajan P, Navar AM, Orringer CE, Polonsky TS, Reynolds HR, Saseen JJ, Shapiro MD, Soffer DE, Tynes SA, Villavaso CD, Virani SS, Wilkins JT. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2026 May 19; 87(19):2624-2757.
Score: 0.209
-
Saseen J, Tweed E, Crawford P. Clinical inquiries. What are effective medication combinations for dyslipidemia? J Fam Pract. 2006 Jan; 55(1):70-2.
Score: 0.206
-
Nair KV, Saseen JJ. Quality assessment of dyslipidemia in managed care: current best evidence should be used to benchmark quality. Ann Pharmacother. 2006 Jan; 40(1):124-7.
Score: 0.206
-
Myerson M, Warden BA, Saseen JJ, Paparodis R. Challenges in the Choice of Nonstatin Medications for Low-Density Lipoprotein-C Lowering for Cardiovascular Risk Reduction. J Am Heart Assoc. 2025 Oct 21; 14(20):e044134.
Score: 0.203
-
Wiggins BS, Saseen JJ, Page RL, Reed BN, Sneed K, Kostis JB, Lanfear D, Virani S, Morris PB. Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2016 11 22; 134(21):e468-e495.
Score: 0.109
-
Tuchscherer RM, Nair K, Ghushchyan V, Saseen JJ. Simvastatin prescribing patterns before and after FDA dosing restrictions: a retrospective analysis of a large healthcare claims database. Am J Cardiovasc Drugs. 2015 Feb; 15(1):27-34.
Score: 0.097
-
Alford JC, Saseen JJ, Allen RR, Nair KV. Persistent use of against-label statin-fibrate combinations from 2003-2009 despite United States Food and Drug Administration dose restrictions. Pharmacotherapy. 2012 Jul; 32(7):623-30.
Score: 0.020
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|